Cellular targets of gefitinib.

Targeted inhibition of protein kinases with small molecule drugs has evolved into a viable approach for anticancer therapy. However, the true selectivity of these therapeutic agents has remained unclear. Here, we used a proteomic method to profile the cellular targets of the clinical epidermal growth factor receptor kinase inhibitor gefitinib. Our data suggest alternative cellular modes of action for gefitinib and provide rationales for the development of related drugs.

[1]  V. Vasioukhin,et al.  BRK/Sik expression in the gastrointestinal tract and in colon tumors. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  T. Maniatis,et al.  IKKε Is Part of a Novel PMA-Inducible IκB Kinase Complex , 2000 .

[3]  B. Gusterson,et al.  Cloning and characterisation of cDNAs encoding a novel non-receptor tyrosine kinase, brk, expressed in human breast tumours. , 1994, Oncogene.

[4]  B. Gusterson,et al.  Brk, a Breast Tumor-derived Non-receptor Protein-tyrosine Kinase, Sensitizes Mammary Epithelial Cells to Epidermal Growth Factor* , 1996, The Journal of Biological Chemistry.

[5]  T. Roberts,et al.  The serine/threonine kinase cyclin G-associated kinase regulates epidermal growth factor receptor signaling. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[6]  M. Cotten,et al.  An efficient proteomics method to identify the cellular targets of protein kinase inhibitors , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Ola Engkvist,et al.  Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors. , 2004, Chemistry & biology.

[8]  M. Sliwkowski,et al.  Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor* , 2002, The Journal of Biological Chemistry.

[9]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[10]  A. Ullrich,et al.  Mutation of Threonine 766 in the Epidermal Growth Factor Receptor Reveals a Hotspot for Resistance Formation against Selective Tyrosine Kinase Inhibitors* , 2003, The Journal of Biological Chemistry.

[11]  E. Sausville,et al.  Issues and progress with protein kinase inhibitors for cancer treatment , 2003, Nature Reviews Drug Discovery.

[12]  Krystal J Alligood,et al.  A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib) , 2004, Cancer Research.

[13]  A. Ullrich,et al.  Identification of SRPK1 and SRPK2 as the Major Cellular Protein Kinases Phosphorylating Hepatitis B Virus Core Protein , 2002, Journal of Virology.

[14]  G. Müller,et al.  Evaluation of kinase inhibitor selectivity by chemical proteomics. , 2004, Assay and drug development technologies.

[15]  R. Pazdur,et al.  United States Food and Drug Administration Drug Approval Summary , 2004, Clinical Cancer Research.

[16]  W. Mckenna,et al.  Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas. , 2003, Cancer research.

[17]  K. Gibson,et al.  Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. , 2001, Bioorganic & medicinal chemistry letters.

[18]  M. Cotten,et al.  Chemical Proteomic Analysis Reveals Alternative Modes of Action for Pyrido[2,3-d]pyrimidine Kinase Inhibitors* , 2004, Molecular & Cellular Proteomics.

[19]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[20]  C. Janeway,et al.  RICK/Rip2/CARDIAK mediates signalling for receptors of the innate and adaptive immune systems , 2002, Nature.